BioGPS
  • Home
  • Help
  • Plugins
  • Datasets
  • Sign Up
  • Login
Examples: Gene Symbol(s), Gene Ontology, Splicing plugins, Melanoma datasets
advanced
Home › Dataset Library › Gene expression profiles to predict recurrence in stage II and III colon cancer

Dataset: Gene expression profiles to predict recurrence in stage II and III colon cancer

Purpose: The present study aimed to develop a classification model to predict recurrence in stage II and III colon cancer, using a...

Registered by ArrayExpress Uploader
View Dataset

Purpose: The present study aimed to develop a classification model to predict recurrence in stage II and III colon cancer, using a previously published 128-gene signature on external and independent material. Experimental Design: Microarray gene expression data from 148 patients (37 Danish patients and 111 patients retrieved from the Gene Expression Omnibus, GSE17536) with stage II and III colon cancer were analyzed using Affymetrix Arrays (Affymetrix, Santa Clara, USA). Based on a known 128-gene signature, a classification model was created with the random forest method, using a training set consisting of stage I colon cancers (with localized disease and a good prognosis) and stage IV colon cancers (with metastasis and a poor prognosis). The classifier were built to predict stage II and III colon cancers as either stage I-like (good prognosis) or stage IV-like (poor prognosis). Results: The 3-year relapse-free survival probability (RFS) of stage III patients predicted to have a good prognosis was 79% compared to 55% of patients with a poor prognosis (P = 0.177, log-rank test). The classification model could not stratify stage II colon cancer. The complete dataset representing: (1) the 37 Danish patients (2) the 111 patients retrieved from Series GSE17536 (re-used data), is linked below as a supplementary file. Tumor samples were obtained from 37 patients with stage II and III colon cancer, who underwent colon resection at the Department of Surgery, Roskilde Hospital, Denmark and the Department of Surgery, Bispebjerg Hospital, Denmark between 2001 and 2008. Purified tumor RNA was reverse-transcribed, labelled and hybridized to Affymetrix Human Genome U133 Plus 2.0 GeneChip Array (Affymetrix, Santa Clara, USA) according to the manufacturers instructions and scanned at the RH Microarray Center, Rigshospitalet, University of Copenhagen.

Species:
human

Samples:
37

Source:
E-GEOD-31595

Updated:
Dec.12, 2014

Registered:
Sep.16, 2014


Factors: (via ArrayExpress)
Sample DEATH TUMOR LOCATION ADJUVANT CHEMOTHERAPY GRADE GENDER AGE TNM-STAGE RECURRENCE NUMBER OF LYMPHNODES RESECTED RELAPSE FREE SURVIVAL TIME HISTOLOGY
GSM78267 No right colon yes Moderate diff. female 65 III no 17 47.80 month adenocarcinoma
GSM782674 No left colon no moderately diff. male 79 II no 15 48.45 month adenocarcinoma
GSM784850 no left colon no well diff. female 56 II no 14 48.53 month adenocarcinoma
GSM78485 yes right colon yes poor diff. female 72 III yes 12 5.29 month adenocarcinoma
GSM784852 no left colon no well diff. female 79 II yes 22 28.96 month adenocarcinoma
GSM784853 no left colon no moderately diff. female 68 II no 17 41.03 month adenocarcinoma
GSM784854 no right colon no well diff. male 71 II no 30 38.73 month adenocarcinoma
GSM784855 no left colon no moderately diff. female 71 III no 10 36.23 month adenocarcinoma
GSM784856 no left colon no moderately diff. female 68 III no 18 36.10 month adenocarcinoma
GSM784857 yes right colon no well diff. female 87 II no 12 29.88 month adenocarcinoma
GSM784858 no left colon no moderately diff. female 51 II no 16 38.30 month adenocarcinoma
GSM784860 no right colon no moderately diff. male 64 II no 16 36.03 month adenocarcinoma
GSM784862 no right colon no poor diff. male 66 III no 20 38.33 month adenocarcinoma
GSM784865 no right colon yes poor diff. male 62 III no 17 38.92 month adenocarcinoma
GSM784867 no right colon no moderately diff. male 79 II no 14 40.11 month adenocarcinoma
GSM78487 no right colon no well diff. female 65 II no 19 36.36 month adenocarcinoma
GSM784873 no right colon yes not specified female 74 III yes 18 40.60 month mucinous adenocarcinoma
GSM784875 no right colon yes moderately diff. female 62 III no 31 36.36 month adenocarcinoma
GSM784878 no right colon yes poor diff. male 64 III no 21 36.10 month adenocarcinoma
GSM78488 yes left colon yes well diff. male 72 III yes 13 20.38 month adenocarcinoma
GSM784884 no left colon no well diff. female 63 II no 12 36.59 month adenocarcinoma
GSM784885 yes right colon no moderately diff. male 88 III yes 12 11.67 month adenocarcinoma
GSM784886 no right colon no not specified female 77 III no 5 112.11 month mucinous adenocarcinoma
GSM784887 yes right colon no moderately diff. male 73 II no not specified 26.56 month adenocarcinoma
GSM784888 yes left colon no poor diff. male 80 II yes 4 6.41 month adenocarcinoma
GSM784889 no left colon no moderately diff. female 80 III no 7 109.84 month adenocarcinoma
GSM784890 no left colon no moderately diff. male 78 II no 16 100.86 month adenocarcinoma
GSM78489 yes left colon yes moderately diff. female 70 III yes 10 42.05 month adenocarcinoma
GSM784892 yes right colon no poor diff. male 91 II no 24 38.14 month adenocarcinoma
GSM784893 no right colon no moderately diff. female 82 II no 15 99.19 month adenocarcinoma
GSM784894 yes right colon no moderately diff. female 90 II no not specified 33.01 month adenocarcinoma
GSM78490 no right colon yes moderately diff. female 83 III no 8 101.82 month adenocarcinoma
GSM784902 yes right colon no moderately diff. female 81 II yes 12 4.60 month adenocarcinoma
GSM784903 yes right colon no moderately diff. female 89 II no 11 83.11 month adenocarcinoma
GSM784904 no left colon yes moderately diff. male 69 III no 17 96.82 month adenocarcinoma
GSM784905 no right colon no moderately diff. male 85 II no 15 96.82 month adenocarcinoma
GSM784906 no right colon yes well diff. female 89 III no 10 43.27 month adenocarcinoma

Tags

  • cancer
  • colon
  • colon cancer
  • disease
  • external
  • genome

Other Formats

JSON    XML
  • About
  • Blog
  • Help
  • FAQ
  • Downloads
  • API
  • iPhone App
  • Email updates
© 2025 The Scripps Research Institute. All rights reserved. (ver 94eefe6 )
  • Terms of Use